MediWound Ltd. (MDWD) Receives Consensus Recommendation of “Buy” from Analysts
MediWound Ltd. (NASDAQ:MDWD) has earned an average recommendation of “Buy” from the six brokerages that are currently covering the stock. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $13.25.
A number of equities research analysts recently weighed in on the stock. Jefferies Group cut their price objective on shares of MediWound from $15.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, July 29th. Zacks Investment Research cut shares of MediWound from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. Finally, Wells Fargo & Co. assumed coverage on shares of MediWound in a research note on Wednesday, August 17th. They set an “outperform” rating and a $14.00 price objective on the stock.
MediWound (NASDAQ:MDWD) remained flat at $6.90 during midday trading on Monday. The stock had a trading volume of 2,007 shares. MediWound has a 12 month low of $5.66 and a 12 month high of $10.47. The firm’s market capitalization is $150.77 million. The stock’s 50 day moving average price is $7.57 and its 200 day moving average price is $7.76.
MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.11. MediWound had a negative net margin of 2,332.07% and a negative return on equity of 103.14%. The company had revenue of $3.36 million for the quarter, compared to the consensus estimate of $0.45 million. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. MediWound’s revenue for the quarter was up 115.8% compared to the same quarter last year. On average, equities research analysts forecast that MediWound will post ($1.02) EPS for the current year.
Large investors have recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in shares of MediWound by 19.4% in the first quarter. Renaissance Technologies LLC now owns 49,800 shares of the biopharmaceutical company’s stock valued at $402,000 after buying an additional 8,100 shares during the period. United Services Automobile Association increased its stake in MediWound by 125.9% in the second quarter. United Services Automobile Association now owns 123,440 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 68,800 shares during the last quarter. Wellington Management Group LLP increased its stake in MediWound by 10.7% in the first quarter. Wellington Management Group LLP now owns 1,044,703 shares of the biopharmaceutical company’s stock valued at $8,431,000 after buying an additional 100,723 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in MediWound during the second quarter valued at about $13,302,000. Hedge funds and other institutional investors own 26.48% of the company’s stock.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.
Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.